Life Sciences Archive » December, 2017

Life Sciences - December, 2017

240 articles

• Ex-Katten Attorney Convicted Of Aiding Shkreli Fraud
• Ex-Katten Atty's Trial Heads To Jury For The Holidays
• Self-Made IP No Longer Deemed Capital Asset In New Tax Law
• Eli Lilly Escapes Testosterone MDL With Settlement Deal
• Judge Throws Out $150M AbbVie AndroGel Verdict
• Roche Inks $1.7B Deal For Calif. Cancer-Drug Maker
• La. Not Bound By Flonase Antitrust Settlement: 3rd Circ.
• Trump Signs $1.5T Tax Cut Legislation
• 5 Most-Read Legal Industry Articles Of 2017
• Novartis Could Be On Hook For Generic Drug: Calif. Justices
• NC Sues Insys Over Scheme To Push Powerful Opioid
• Ex-Katten Atty Cites 'Walls' Of Doubt As Trial Nears End
• Landlord Issues Punted In Vitamin World's $28M Sale Order
• Shire FCA Deal Doesn't Cover 'Unique' Claims, Relator Says
• Raytheon Says Settlement Ended Bedford Clean-Up Liability
• Hospitals Urge Judge to Halt $1.6B Cut to Drug Payments
• Calif. Bank & Trust Beats Suit Over Depositor's Ponzi Scheme
• Aerkomm Hopes $40M Public Offering Will Fly With Investors
• Arbitrators Can't Demand Third-Party Docs, 9th Circ. Says
• Spoliation Scrutiny: Disparate Standards For Distinct Mediums
• Full Fed Circ. Won't Review Boston Sci Win In $200M IP Suit
• Cancer-Focused Biopharma Co. Tallies $60M Funding Round
• Where 5 Top MDLs Stand At The End Of 2017
• Valeant Gets To Arbitrate Ex-CEO's 3M Unpaid Shares Claim
• Allergan Seeks To Pause Antitrust Suits Pending MDL Call
• The Latest FDA Move To Limit Digital Health Software Regs
• Feds To Retry Ex-Biotech Exec After Mistrial In Fraud Case
• Drugmakers Ducked $1.3B In Medicaid Rebates, OIG Says
• Tribunal Lacked Power To Nix $135M Claim, Softgel Co. Says
• Greebel 'Greased Wheels' For Shkreli, Feds Say At Closing
• Nutraceutical Investors Demand Appraisal After $446M Buy
• J&J Fined €25M Over French Generic Drug Smear Campaign
• Sens. Target Small Drugmaker Over 300-Fold Price Hike
• United Therapeutics Settles Charity-Kickback Claim For $210M
• Judge OKs $700K Settlement Over Montel-Endorsed Clothes
• Baxter Healthcare's Waste Overpolluted Water, Ill. AG Says
• Boehringer To Pay $13.5M To End Off-Label Marketing Claims
• TM Dilution Claims Over Trojan Condoms' 'XOXO' Tossed
• Medical Co. Slams Whistleblower's 'Backward' Appeal Bid
• Bayer, Merck Accused Of Falsely Advertising Sunblock's SPF
• Exploring Viability Of 'Diagnose And Treat' Method Claims
• 'Patent Dance' Ruling Means Sponsors Must Plan Ahead
• House Sends $1.5T Tax Cut Bill To Trump's Desk
• FCPA Enforcement Picks Up In 2nd Half Of 2017
• Hearing The Need For More Women's Voices In The Courtroom
• Telehealth In 2017: What Changed And What's Ahead
• GOP Tax Cut Bill Nears Finish Line After Senate Passage
• With Another Flap, Greebel Fraud Trial Heads To Closings
• FCA Suit Against Sleep-Testing Co. Rouses The Feds
• Sandoz Gets Early Win In Amgen IP Dispute Over Neulasta
• Meningitis Outbreak MDL, $200M Settlement Fund Near End
• FDA Warning Wire: Zika, Tattoos, Syringes, Supplements
• Zurich Doesn't Owe On Sexual Harassment Payouts: Judge
• Deals Rumor Mill: CJ HealthCare, Vitamin World, Time Warner
• Dr. Reddy's To Pay $5M To End Feds' Packaging Safety Suit
• MVP: Fish & Richardson's Dorothy Whelan
• House Must Vote Again On Final GOP Tax Bill
• Grant & Eisenhofer Fee Fight Halts $73M Celgene FCA Payout
• Tribe, Generics Spar Over PTAB Amici In Allergan Patent Row
• Ex-Biotech Exec Denies Tie To Mass. Securities Scheme
• FDA Vows Crackdown On Homeopathic Treatments
• Sandoz Says Neulasta Biosimilar Doesn't Infringe Amgen IP
• 2nd Circ. Affirms Dismissal Of FCA Suit Against Amgen
• PTAB To Rehear Cook Challenge To Internal-Bleed Device IP
• Bayer Slams 'Killinnazis' Posts In $28M Xarelto Injury Case
• Fed. Circ. Upholds Genzyme's Win In Stem Cell Patent Case
• $10M Pepcid Patent Verdict Nixed As Judge Reverses Herself
• MVP: Gibson Dunn's Jane Love
• Prevagen Maker Must Face Certified Class In Labeling Suit
• 40 Years Of FCPA
• How 2 Devices And 1 Domain Changed My Practice In 2017
• Fed. Circ. Says PTAB Erred In Axing Hospital Bed Patent
• Top Product Liability Cases Of 2017
• Bayer, Belmora Spar Over TM, Antitrust Bids In Flanax Feud
• Russian Award's OK Is Nigh For No-Show Pharma Biz
• Pa. Man Cops To Celator Insider Trading Scheme
• Mitsubishi Says Generics Co.'s ANDA Infringes Diabetes Med
• Artificial Knee Co. Can't Trim $16M Injury Damages Further
• Could A High Court Case Blunt AIA Tribal Immunity Defense?
• 17 Pharma And Food Tweets That Left A Mark In 2017
• PTAB Invalidates Hologic Patent, Rejects Claim Fixes
• Subsidiaries May Sway Patent Case Jurisdiction In Del.
• Final GOP Tax Bill Settles On 21% Corporate Rate
• Health Hires: Holland & Knight, EBG, Quarles, Ciitizen
• A Chat With Orrick COO Laura Saklad
• Alternative Fees: My Experience At Bartlit Beck
• Litigation Is Not The Solution To The Opioid Epidemic
• MVP: Goodwin's Stuart Cable
• US Calls Off The Dogs Following Thailand's IP Tweaks
• The Biggest Pennsylvania Court Decisions In 2017
• Does Indication-Specific Pricing Fit Generics With Carveouts?
• Jurors Should Have An Active Role In Trials
• Gov't Misconduct Claims Blocked From Ex-Katten Atty Trial
• NY High Court Says 'Wrongful Birth' Claims Start At Birth
• Mass. City Latest To Sue Pharma Cos. Over Opioid Crisis
• 3 Takeaways As Fed. Circ. Limits Biosimilar Lawsuits
• ITC To Probe Intraoral Scanners Over Patent Infringement
• Xarelto Bellwether Loser's New Trial Bid Rejected By Judge
• Boston Scientific Settles Nearly 350 Pelvic Mesh Suits
• Usage Of Uterine Device Down Since Warning, FDA Says
• MVP: Sullivan & Cromwell's Matthew Hurd
• Insurer Doesn't Owe For $2.8M Suit Against Medical Co.
• NC Prosthetics Co. Ran $12M Medicaid Fraud, Gov't Says
• J&J Unit Hit With $15M Pelvic Mesh Verdict In NJ
• Meningitis Fraudster Says Feds' Push For $133M Must Wait
• 40 Years Of FCPA: An Update From The DOJ
• Why Information Governance Is More Important Than Ever
• A Review Of Massachusetts' Marijuana Industry In 2017
• Biosimilar Act Trumps State Laws, Fed. Circ. Rules
• Cosmetic Companies Must Plan For New Regulation  
• Partial Win Likely For Celgene In Mylan Antitrust Suit
• BigLaw Is Behind The Automation Curve
• Jury Urged To Punish J&J With Pelvic Mesh Trial Verdict
• 2nd Circ. Axes Pharma Exec's Fraud Convictions
• Cancer Immunotherapy Co. Nabs $62M To Advance Research
• Apotex Challenges Amgen Cancer Biologic Patent As Obvious
• Purdue Loses Bid To Fuse Jumble Of OxyContin Patent Suits
• Pa. Justices Won't Revive Zoloft Birth Injury Suit
• GSK Beats Heart Attack Suit In Diabetes Drug MDL
• Lessons On Losses From 3 Recent FCA Settlements
• Medtronic To Pay $12M To End Deceptive Advertising Suit
• How District Courts Split Over 'Infringing Acts'
• Biopharma Co. Allakos Nabs $100M In Funding Round
• 40 Years Of FCPA: Compliance, Past And Future
• Jury Sides With SEC, Finds Syringe Maker Juiced Stock
• State AGs Fight To Block Trump's Birth Control Rules
• Biopharm Ex-CEO Used Travel Funds For Hooters, SEC Says
• Ill. Doctor Gets 14 Mos. For Illegal Drug Distribution
• Calif. Surrogacy Agency Not Covered For Negligence Suit
• GOP Introduces 5 Bills To Delay Affordable Care Act Taxes
• Amgen Whistleblower Was Original Source, 2nd Circ. Told
• Retailers Settle Claims Against Teikoku In Lidoderm MDL
• Split Del. Justices OK Denial Of $50M Drug Approval Bonus
• Pharma Cos. Settle Pa. Skelaxin Pay-For-Delay Fight
• Fed. Circ. Affirms PTAB Ax Of Daiichi's Heart Drug Patents
• FDA Warning Wire: Chocolate 'Snuff' Sold As Street Drug Sub
• Actavis Asks Calif. Justices To Revive Opioid Coverage Bid
• 40 Years Of FCPA: Cross-Border Efforts And Growing Risk
• Judging A Book: Cooke Reviews 'Constance Baker Motley'
• Keeping Your Law Library Relevant In The Age Of Google
• Fed. Circ. Says It Can't Review PTAB Re-Exam Terminations
• Surgeon Tells Jury Complications Not Limited To J&J Mesh
• 6 Things You Need To Know About Millennial Jurors
• Why Investors Are Taking The Leap To 3rd-Party Funding
• Has Litigation Finance Shed Its Stigma?
• What Your Colleagues Think Of Litigation Finance
• Law Firm Doesn't Owe For GSK Contempt Order, 3rd Circ. Told
• Ex-Katten Atty's Expert Defends No-Work Consulting Deals
• Fed. Circ. Upholds Ruling Axing Forest's Namenda Patents
• Retailers Defend Solodyn MDL Claims Against Medicis
• Convicted Pharmacist's Wife Wants To Keep Money, House
• Endo Escapes Faulty Pelvic Mesh Suit On Appeal
• Supreme Court Won't Review Lawyer's Stock Fraud Conviction
• 1st Circ. Won't Revive $28M Monsanto PCB Liability Suit
• FDA Issues Final Guidance On Drug Names In Ads
• Puma Biotech Investor Class Certified In Stock Drop Case
• 40 Years Of FCPA: A View From The Monitorship Trenches
• The Law Firms Of The 2017 MVPs
• Law360 MVP Awards Go To Top Attorneys From 78 Firms
• Investor Hit With $38M Judgment For 'Smear' Campaign
• Pharma Group Sues Calif. Over Drug Pricing Law
• NJ High Court OKs Roche's Bids To Review Accutane Rulings
• Innoviva Investor Wins Board Seats In Chancery Proxy Suit
• Katten Atty Says He Never Saw Greebel Break The Law
• Patheon Says Rival Can't Recover $135M Over Softgel Pact
• Biotech Denali Therapeutics Tops 3 IPOs Totaling $506M
• Gilead Snaps Up PE-Backed Biotech In $567M Deal
• 40 Years Of FCPA: The Untold Story Of The Resource Guide
• Real Estate Brokerage Leads 3 IPOs Set To Raise $762M
• Deals Rumor Mill: Bayer, Toshiba, Alexion Pharmaceuticals
• Contractor Sues For $21M Over Bio Warfare Facility Work
• FDA Unveils New Policies On Digital Health Oversight
• Amgen Urges Full Fed. Circ. Hearing On Repatha Patents
• Feds Blast Ex-Pharmacist's Acquittal Bid In Meningitis Row
• Ex-Katten Atty Was Corporate Ace At Firm, Jury Hears
• Puma Exec's Brother Traded On Cancer Drug Info, SEC Says
• Covington Lures Back FDA Drug Quality Leader
• 40 Years Of FCPA: A Journey From Conviction To Dismissal
• 4th Circ. Frees Pfizer From Antitrust Suit Over Celebrex Patent
• 9th Circ. Vacates Drug Liability MDL Ruling Favoring Merck
• 2 Biotech Cos., Payday Lender Tap IPO Market For $307M
• Lab CEO Can't Be Named In FCA Retaliation Suit, Court Says
• Israel Chemicals Snags Roughly $1B In Sale To PE Firm
• Attys Get $4.5M Of $22M Aegerion Drug Marketing Settlement
• The Biggest Patent Cases Of 2017
• My Strangest Day In Court: The Shkreli Trial
• Prosecution In Greebel Case Rests After Hearing Last Witness
• 9th Circ. Affirms Doc's Rx Conviction But Nixes Sentence
• JPML Sends Opioid MDL To Northern Ohio
• Allergan Says Shire Suit Upends 'Very Fabric' Of Antitrust Law
• Tribe Hits Pharma Cos. Over Opioid Crisis
• Insurer Can't Recoup $9M Payout For Drug Theft: 3rd Circ.
• Opioid Suits Are The New Tobacco Litigation, Atty Says
• $28M Philly Xarelto Verdict Ripe For Reversal, Attys Say
• Gilstrap Can't Erase Jury's Patent Verdict, Fed. Circ. Hears
• 40 Years Of FCPA: The Siemens Lesson — Tillerson Is Right
• GAO Urges VA To Improve Medical Supply Purchase Program
• Celltrion Wants Janssen To Give Up Docs From Samsung Suit
• Roxane Fights Vanda Antipsychotic Dose Patent In Fed. Circ.
• Pharma Co. Slams Patent Challenge Standing In Fed. Circ.
• $110M Talc Verdict's Survival Eases Way For Out-Of-Staters
• Bovine Breeding Tech Co. Seeks To Revive Patent Claims
• Ex-Shire Employees Seek To Duck Trade Secrets Complaint
• Pa. Judge Affirms Jurisdiction On Out-Of-State Mesh Cases
• 9th Circ. Refuses To Rethink Ex-InterMune CEO's Conviction
• Mayer Brown Advises Nestle's $2.3B Deal For Nutrition Co.
• Merck Aims To Sink Cert In $250M Sex Bias Class Action
• 40 Years Of FCPA: The Rise In International Enforcement
• Beware Marketing Cannabidiol Products: FDA Is Watching
• Buyer Class Fights Allergan Over Causation In Antitrust Row
• J&J, Bayer Hit With $28M Verdict In 1st Xarelto Loss
• Montana AG Hits Purdue With Opioid Suit
• Tech, Generics Cos. Spar With Tribes Over Allergan At PTAB
• Patent Args Should've Gone To Jury, Fed Circ. Told
• Investors Tell 1st Circ. Sarepta Hid FDA Testing Issues
• Fla. Compounding Pharmacy Can't Escape Tricare FCA Suit
• FBI Pressured Witness With Surprise Visit, Greebel Atty Says
• Janssen Rips Patent Owner's Bid To Appeal Mid-Case
• Proactive Brand Protection Strategies For Pharma Innovators
• TPG Sweetens Deal For Medical Device Co. Exactech To $737M
• High Court Won't Hear Dow's Appeal Of $455M Bayer Award
• Justices Ask SG To Weigh In On Merck's Fosamax MDL
• 40 Years Of FCPA: Highlights From The 1st Corporate Trial
• Ex-Pharma Staffing Exec Wants Out Of Noncompete Suit
• Plavix Ruling Raises Learned Intermediary Questions
• Biotech Cos. Among 5 IPOs That Could Surpass $580M
• Pfizer, Dana-Farber Win Bid For Bristol-Myers Docs In IP Suit
• Philly Jury Set To Deliberate In Xarelto Injury Case
• 9th Circ. Says Gov't Still Party To Closed Lawsuit In FCA Row
• Pfizer Tells 2nd Circ. Feds Lack Immunity In $8.3M Tax Row
• FDA's Focus On Competition May Boost FTC Enforcement
• Deals Rumor Mill: Merck, Mednax, Volkswagen
• 40 Years Of FCPA: The Strange Case That Started It All
• Drug Co. Wants FOIA Answers From NIH Over Biotech Ties
• InSys Investor Suit Put On Hold As Criminal Action Plays Out
• Texas Justices Won't Hear Suit Over Newborn's Genetic Test
• Vitamin Cos. Want New Trial After $6.8M IP Verdict
• Feds Want Shkreli To Forfeit $7.3M, Wu-Tang Clan Album
• Pa. Judge Says No Preemption In Auxilium Testosterone Case
• MDL Hearing Signals A New Phase For Opioid Suits